Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Over the last decade, clinical registries have significantly contributed to the pool of evidence
that supports management decisions in patients with multiple sclerosis. Being the largest …

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a
profound effect on disease activity. The current treatment guidelines only recommend high …

Multiple sclerosis is a leading cause of neurological disability in adults. Heterogeneity in
multiple sclerosis clinical presentation has posed a major challenge for identifying genetic …

Background High-efficacy disease-modifying therapies have been proven to slow disability
accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on …

Purpose: The study evaluated a group-based cognitive behavioral intervention aimed at
promoting the quality of life and the psychological well-being of recently diagnosed multiple …

Objective: To examine the relationship between coping strategies (problem solving,
emotional release, and avoidance) and adjustment (health-related quality of life, depression …

Background Perivascular space (PVS) is associated with neurodegenerative and
neuroimmune diseases. Multiple sclerosis (MS) is traditionally a neuroimmune disease …

Background The genetic drivers of multiple sclerosis (MS) clinical course are essentially
unknown with limited data arising from severity and clinical phenotype analyses in genome …

BACKGROUND The ability to better predict disease progression represents a major unmet
need in multiple sclerosis (MS), and would help to inform therapeutic and management …